STOCK TITAN

C4 Therapeutics Inc - CCCC STOCK NEWS

Welcome to our dedicated news page for C4 Therapeutics (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect C4 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of C4 Therapeutics's position in the market.

Rhea-AI Summary
C4 Therapeutics reported financial results for Q3 2023, with total revenue of $11.1 million, compared to $6.8 million in Q3 2022. The company's cash, cash equivalents, and marketable securities totaled $246.4 million as of September 30, 2023, providing runway into the second half of 2025. The ongoing Phase 1/2 trials of CFT7455 and CFT1946 will be prioritized, while CFT8634 will not advance due to insufficient single agent efficacy in synovial sarcoma and SMARCB1-null tumors. The company also provided updates on its other clinical trials and collaborations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.41%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
-
Rhea-AI Summary
C4 Therapeutics appoints Kendra Adams as CFO, succeeding Lauren White. Adams brings extensive experience in financial and strategic planning in the biotechnology sector. C4T looks forward to leveraging her expertise to advance their pipeline of degrader medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.86%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
earnings
-
Rhea-AI Summary
C4 Therapeutics, Inc. (C4T) Announces Inducement Grants of Non-Qualified Stock Options to New Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
none
-
Rhea-AI Summary
C4 Therapeutics announces FDA clearance for its investigational new drug CFT8919, a potential treatment for non-small cell lung cancer. The company has entered into an exclusive licensing agreement with Betta Pharmaceuticals for development and commercialization in Greater China. C4T expects to initiate clinical trials outside of China after Betta Pharmaceuticals' Phase 1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.31%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
conferences
C4 Therapeutics Inc

Nasdaq:CCCC

CCCC Rankings

CCCC Stock Data

552.24M
52.51M
14.22%
68.09%
4.32%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Watertown

About CCCC

c4 therapeutics is an early stage drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. the centerpiece of our approach is the degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system.